Cell reports · 2020
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wan Jinkai, Xing Shenghui, Ding Longfei, Wang Yongheng, Gu Chenjian, Wu Yanling, Rong Bowen, Li Cheng, Wang Siqing, Chen Kun, He Chenxi, Zhu Dandan, Yuan Songhua, Qiu Chengli, Zhao Chen, Nie Lei, Gao Zhangzhao, Jiao Jingyu, Zhang Xiaoyan, Wang Xiangxi, Ying Tianlei, Wang Haibin, Xie Youhua, Lu Yanan, Xu Jianqing, Lan Fei
Аннотация
Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC50 below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC50 within 10 nM, and the best one, 414-1, with IC50 of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.